Introduction
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Immunopotentiation was first reported to prevent habitual Miscarriage Immunotherapy Trialists Group* abortion in 1981 (Beer et al., 1981; Taylor and Faulk, 1981) . Despite 14 years of use, the efficacy remains in doubt.
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Comparative prospective trials have claimed this treatment to
Tel Hashomer and University of Tel Aviv, Tel Aviv, Israel be beneficial (Mowbray et al., 1985) , whereas others (Cauchi et al., 1991a; Ho et al., 1991) have disputed the efficacy of 1 To whom correspondence should be addressed immunization. Immunologically mediated abortions have been Rather than investigate whether paternal leukocyte poorly defined. At present no reliable laboratory test is available immunization improves the live birth rate in women to diagnose immunologically mediated abortions, and no with three or more abortions, we analysed the results of clinical criteria have been used to classify recurrently aborting patients expected to have a poor outcome in a subsequent women. Therefore treatment has been given to all women with pregnancy if untreated, i.e. women with five or more three or more unexplained pregnancy losses. However, three abortions and no anti-paternal complement-dependent abortions can occur by chance, and the subsequent live birth antibody (APCA) at initial testing. The analysis included rate is~50-60%. With such odds, it is extremely difficult to the results of patients treated by us over the last 8 years
show that any form of treatment has a beneficial effect, and and the results of randomized and non-randomized trials any trial would require large numbers of patients. The largest reported by the Recurrent Miscarriage Immunotherapy such trial is the worldwide meta-analysis on Ͼ400 patients Trialists Group. Patients with a previous live birth were from double-blind randomized studies [Recurrent Miscarriage classified into two groups: secondary aborters if there was Immunotherapy Trialists Group (RMITG), 1994], which an initial live birth followed by miscarriages, or tertiary showed an~10% increased incidence of live births in aborters if there were miscarriages followed by a live birth immunized patients. It concluded that immunization might and at least three subsequent miscarriages. The results partially correct a widely prevalent condition or that were evaluated separately for primary, secondary and immunization may be highly effective, but for only a small tertiary aborters who demonstrated APCA activity as a number of patients who have the condition. result of immunization. The 107 primary aborters had
We reasoned that in order to show whether immunization double the live birth rate if immunized, with an overall benefit of 31%. The 45 tertiary aborters had an almost has a beneficial effect, it is necessary to define a group 3-fold increase in the live birth rate, with an absolute of patients who have a relatively poor prognosis. Various benefit of 50%. The number of patients needed to treat to factors have been reported to affect the subsequent live achieve one extra live birth was three to four primary birth rate, such as the number of previous miscarriages, the aborters or two tertiary aborters. Immunization had little presence of a previous live birth, the time taken to conceive beneficial effect in secondary aborters but was effective in after immunization, patient age, the presence of anti-paternal preventing abortion in primary or tertiary aborters with complement-dependent antibody (APCA) and luteinizing five or more abortions.
hormone (LH) concentrations (Carp et al., 1990a (Carp et al., ,b, 1995 ; Key words: habitual abortion/immunopotentiation/leukocyte Cowchock et al., 1990; Cauchi et al., 1991b; RMITG, immunization 1994) . The most important predictive factor is the number of previous miscarriages. Each subsequent miscarriage lowers the live birth rate by 23% (RMITG, 1994 birth than a patient with three miscarriages (Carp, 1993; Carp Data Submitters: K. Aoki, Nagoya, Japan; H.J.A. Carp, Tel et al., 1993; Daya and Gunby, 1994; RMITG, 1994 (Carp, 1994; RMITG, 1994 Etievant et al., 1988; Carp et al., 1990a,b; Carp, 1994 Patients were classified as primary aborters if they had had no previous live births, or secondary aborters if they had experienced a Values in parentheses are the proportion of patients with five or more abortions.
live birth followed by abortions. We also classified a third group of a Primary ϭ no previous live births; secondary ϭ live birth followed by patients, termed tertiary aborters (Carp, 1994) , who had experienced abortions; tertiary ϭ abortions followed by a live birth followed by at least abortions followed by a live birth and at least three subsequent three abortions.
abortions. These patients have not been defined previously as a distinct group, but had been included as secondary aborters.
cies) but not in the secondary aborter (who has one or more with 95% confidence limits (Fleiss, 1981) . It was calculated as the It consisted of patients immunized with paternal leukocytes or patients number of live births as a proportion of the total number of patients considered suitable for immunization but who decided to forgo immunized, relative to the proportion of live births in non-immunized immunization for various reasons. The international register, which patients. The 95% confidence intervals were calculated and expressed originally included patients from our centre, was modified by on a log scale. excluding these patients (because they were included in our register). The international register was then divided into two groups: patients from randomized studies and those from non-randomized
Results
studies. The randomized register comprised patients reported by nine
The total number of patients in each register is summarized centres. The non-randomized register was drawn from seven centres in Table I . It can be seen that our Tel Aviv register had a (one centre, Taiwan, reported randomized and non-randomized patients). The method of data collection for the international register higher proportion of patients with five or more abortions than has been fully described previously (RMITG, 1994) . Briefly, centres the other two registers.
practising paternal leukocyte or other forms of immunopotentiation Figure 1 shows that the subsequent live birth rate in nonfor recurrent miscarriage submitted data forms with 140 variables for immunized patients was related to the number of previous each patient, including history, details of the investigation and abortions. As expected, the patients with five or more abortions treatment. These data were entered into a computerized database had a lower live birth rate than those with three abortions in using the SPSS program (SPSS Inc., Chicago, IL, USA).
each of the three registers. When the non-immunized patients
The regimen of immunization varied between centres, but most from all three registers were taken together as a whole, it was used the method described by Mowbray et al. (1985) . The regimen seen that the live birth rate fell from 63% for patients with of immunization and APCA testing used at the Sheba Medical Center three abortions to 34% for patients with five or more abortions.
has been fully described elsewhere (Carp et al., 1990a,b) . Briefly, Taken separately, the live birth rate fell from 54 to 30% in the immunizations were prepared from 100 ml samples of heparinized blood. The leukocytes were separated by Ficoll-Hypaque density Tel Aviv patients, from 60 to 29% in the randomized patients, and from 74 to 48% in the non-randomized patients (without to APCA positive after immunization or remained seronegative. any correction for other predictive factors).
The non-randomized studies comprised 201 patients; only 39 Details of the patients with five or more abortions who were (19.4%) could have their results analysed. In our 148 patients, included in the analysis are summarized in Table II . There 110 with five or more abortions had their results analysed were 96 patients with five or more abortions in the randomized (74%). It can be seen that patient age and the number of studies reported in the international register; only 42 (44%) abortions were similar in the immunized and control patients. could have their results analysed. The other 54 patients either Table III relates the results of patients undergoing had no information available as to whether they seroconverted immunization to those of control patients. A higher live birth rate could be seen in primary and tertiary aborters who were immunized. This difference was statistically significant (P ϭ 0.0015 and 0.002 for primary and tertiary aborters respectively). Immunization had no apparent effect on the subsequent live birth rate in secondary aborters. In fact, the non-immunized secondary aborters fared slightly better than the immunized patients, but this difference was not statistically significant. In the randomized trials, the 25% benefit seen in primary aborters was not statistically significant because of the small sample size. When the randomized and non-randomized trials were taken together, there was a 24% benefit seen in immunized patients. This difference was statistically significant (P ϭ 0.01, Fisher's exact test). When the results from our centre were added, the data reached a higher level of statistical significance (P ϭ 0.0015). Figure 2 summarizes the relative risk in each of the subgroups. Again, the significant difference in live birth rates between the subsequent pregnancies or the results of therapeutic trials. This is probably because these patients constitute only 20-25% of all recurrently miscarrying women. Even the international register contains only 81 patients with five or more abortions. The fact that our register contains a higher proportion of patients with five or more miscarriages than the other three registers may indicate that we have a population at a higher risk for subsequent abortions than most other centres, or that our patients do not easily give up hope. As these patients have a poorer prognosis than women with three abortions (Figure  1 ), they probably require treatment more than their counterparts with three miscarriages. We reasoned that such women are more likely to have a single cause for their abortions. Our preliminary results (Carp, 1993; Carp et al., 1993) and those (Table III) is reflected in high relative risk values, whereas no such effect is seen in secondary aborters in whom no significant birth rate in patients with such a poor prognosis.
benefit of immunization was identified (Table III) .
However, even this group, although selected for its poor prognosis, is not homogeneous, because various predictive factors affect the outcome of subsequent pregnancies in addi-1.37-7.04) for primary and tertiary aborters respectively. The tion to immunization. These criteria include primary, secondary relative risk was also calculated for the randomized and nonor tertiary aborter status and APCA. The tertiary aborter has randomized trials in the international register and found to be been described previously only briefly (Carp, 1994) . All 1.94 (CI 1.12-3.35).
other reports include these patients as secondary aborters. We classified tertiary aborters (those who have a live birth in the Discussion middle of a series of abortions) as a group separate from those women who start their obstetric careers with a live birth. In All papers on this topic published to date have asked whether immunization improves the live birth rate in patients with both this study and our previous study (Carp, 1994) we found that these patients responded differently to immunization than three or more unexplained abortions. Using these criteria, the treatment effect is small and open to various interpretations.
other secondary aborters; hence we felt justified in classifying them as a distinct group. Therefore we chose to analyse the effect in patients with five or more abortions who were expected to have a poor prognosis.
The use of APCA as a marker may be controversial. It is only present in~20% of normal parous women's serum and Women with five abortions, no APCA at initial testing and who were induced to produce APCA as a result of immunizais only produced at or near term in successful pregnancies (Regan, 1988) . In addition it is present in 20% of habitually tion overall showed an absolute benefit of 26%. Patients with primary or tertiary abortions had a 31 and 50% benefit aborting women (Carp et al., 1988; Smith and Cowchock, 1988) . However, the international meta-analysis (RMITG, respectively. This means that three primary aborters or two tertiary aborters need to be treated to obtain one extra live 1994) and we (Carp et al., 1990b) have reported that patients with APCA at initial testing have a 71% subsequent live birth birth. The relative risk of a live birth was 2.04 for primary aborters (CI 1.24-3.58) and 2.92 for tertiary aborters (CI rate without treatment. Consequently treatment is unnecessary, and these patients were excluded from the analysis. Their 1.37-7.04). Secondary aborters did not benefit from this treatment. Hence, there may be factors other than those inclusion would have skewed the results, thus raising the live birth rate of the control patients. Seroconversion to APCA operating in primary and tertiary aborters causing abortion in at least some of these patients.
positive after immunization may also be controversial because APCA is not a prerequisite for a successful pregnancy. Other Patients with five or more abortions have been poorly described in the literature. Kwak et al. (1992) described parameters may be better markers, e.g. mixed lymphocyte reactivity, flow cytometry or even the human embryonic the incidence of antiphospholipid antibodies and antinuclear antibody according to gravidity. Kilpatrick and Liston (1993) antigen associated with spontaneous abortion (Shiraishi et al., 1995) . However, the results of these other parameters were described 26 patients with five or more abortions, but did not relate this group to the outcome of leukocyte immunization.
not available from the registers, making their effect impossible to analyse. Meanwhile, APCA remains the only parameter to They did, however, calculate that the chance of five abortions occurring by chance was only 5%, as opposed to 48% in be widely reported as associated with an improved outcome after immunization (Reznikoff-Etievant et al., 1988 ; Carp women with three or more abortions. Christiansen et al. (1994) described the human leukocyte antigen haplotypes in women et al., 1990a; Carp, 1994; RMITG, 1994; Agrawal et al., 1995) . Hence we felt justified in including this parameter with four or more abortions. Most epidemiological studies of recurrent miscarriage do not mention these patients as a despite reports of a worse prognosis in patients who seroconverted (Smith and Cowchock, 1988) . separate group. No study has described the outcomes of It was difficult to make the test group more homogeneous miscarriages up to 20 weeks requires urgent revision. The patients, type of abortion and laboratory markers of immunizabecause we could not control for the other factors that influence the response to immunization, such as maternal age, time taken tion need to be defined more strictly. Assessors of future results will then be able to ask whether there is a subgroup to conceive and follicular phase LH concentrations (Carp et al., 1995) . Only four patients were reported to have a raised LH of patients who benefit from immunotherapy. Prospective randomized trials can then be carried out in strictly defined concentration in the international register, and the number of patients with a normal LH concentration was not quoted. We and matched populations with a poor prognosis. Only such a trial will be able to define accurately the place of immunodid not correct the figures for maternal age, because the patient with five or more abortions is more likely to be in the higher potentiation (or any other form of treatment) in recurrent miscarriage. If we continue to ask whether immunotherapy age group. However, Table II shows that the mean age and the age range were similar in all groups. We did not correct increases the chance of a live birth in women with three or more abortions, we will only be able to conclude that for the time taken to conceive because this cannot be foreseen prior to treatment and cannot therefore influence the decision immunotherapy is not a panacea. At present it seems that the patient most likely to benefit is the primary or tertiary aborter as to whether to treat. The time taken to conceive was longer in our patients than in the two other registers (Table II) .
who is APCA negative. The patient whose immune parameters (such as APCA) change after immunization is more likely to However, this was not reflected in the outcomes of the subsequent pregnancies. The results of our patients were benefit. However, booster immunizations may be necessary to induce seroconversion. It should also be borne in mind that certainly not worse than in the other groups.
Originally we intended analysing the randomized trials allogenic immunization is the only form of treatment that has been assessed in these very high risk patients, and in our view alone. However, this was not feasible because very few patients had complete details available as to whether they seroconverted it is indicated in the primary and tertiary aborters. to APCA positive. Most patients were treated by Mowbray et al.'s (1985) regimen and remained APCA negative. In the
